Identifying the Risk of Breast Cancer in Childhood Cancer Survivors

Video

Zhaoming Wang, PhD, bioinformatics scientist, Department of Computational Biology, St. Jude Children’s Research Hospital, discusses a study that is identifying the risk of breast cancer in survivors of childhood cancer.

Zhaoming Wang, PhD, bioinformatics scientist, Department of Computational Biology, St. Jude Children’s Research Hospital, discusses a study that is identifying the risk of breast cancer in survivors of childhood cancer.

Chest irritation in female pediatric patients with cancer is a major risk factor for breast cancer as survivors move into adulthood, explains Wang. Literature has also reported a risk of breast cancer for these patients after treatment with chemotherapy, but the genetic risk is not known.

In addition to whole-genome sequencing of rare, highly penetrant mutations in the predisposition genes, Wang says that investigators also looked at the genetic variants in these patients. This was done in an attempt to model risk of the commonly used demographic clinical variables and genetic factors, including rare mutations and common variants. From there, a polygenic risk score with 172 variants was built. Wang explains that each patient will receive a number to measure their risk of developing breast cancer in the general population.

The data used in this analysis was taken from the St. Jude Lifetime Cohort Study whole-genome sequencing data. Wang says it is the first time that this type of score was applied to survivors of childhood cancer.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,